Spots Global Cancer Trial Database for ewing sarcoma
Every month we try and update this database with for ewing sarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | NCT05605522 | Pancreatic Duct... Squamous Cell C... Colorectal Canc... Gastric Cancer Ewing Sarcoma NTSR1 Expressin... Neuroendocrine ... | [225]-FPI-2059 [111In]-FPI-205... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | NCT02867592 | Adrenal Cortica... Alveolar Soft P... Central Nervous... Childhood Clear... Clear Cell Sarc... Ewing Sarcoma Hepatoblastoma Hepatocellular ... Osteosarcoma Recurrent Adren... Recurrent Alveo... Recurrent Clear... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Kidne... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Recurrent Renal... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Refractory Adre... Refractory Alve... Refractory Clea... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Oste... Refractory Prim... Refractory Prim... Refractory Rena... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory Wilm... Renal Cell Carc... Rhabdomyosarcom... Soft Tissue Sar... Solid Neoplasm Thyroid Gland M... Wilms Tumor | Cabozantinib Cabozantinib S-... Pharmacological... | 2 Years - 30 Years | National Cancer Institute (NCI) | |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | NCT03190174 | Ewing Sarcoma PEComa Epithelioid Sar... Desmoid Tumor Chordoma Non Small Cell ... Urothelial Carc... Melanoma Renal Cell Carc... Squamous Cell C... Hepatocellular ... Classical Hodgk... Colorectal Canc... MTOR Activating... | Nab-Rapamycin Nivolumab | 12 Years - | Sarcoma Oncology Research Center, LLC | |
| Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas | NCT00043979 | Sarcoma | F-18 Fluorodeox... therapeutic all... cyclophosphamid... cyclosporine doxorubicin hyd... etoposide fludarabine pho... melphalan prednisone sirolimus tacrolimus vincristine sul... peripheral bloo... Filgrastim Peripheral Bloo... | 5 Years - 35 Years | National Institutes of Health Clinical Center (CC) | |
| Clinical Evaluation for Sarcoma Originated From Bone | NCT03358992 | Sensitivity Specificity Histological Re... Survival | - | Peking University People's Hospital | ||
| Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | NCT04337177 | Solid Tumors Neuroblastoma Rhabdomyosarcom... Ewing Sarcoma Hepatoblastoma Medulloblastoma | VAL-413 Temozolomide | 1 Year - 30 Years | Valent Technologies, LLC | |
| Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas | NCT05210374 | Relapsed Sarcom... | Disulfiram Copper Gluconat... Liposomal Doxor... | 1 Year - | Case Comprehensive Cancer Center | |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | NCT03715933 | Solid Tumors Malignant Pleur... Gastric Adenoca... Colorectal Aden... Sarcoma Pancreatic Aden... Ewing Sarcoma Chondrosarcoma GIST SDH-deficient S... | INBRX-109 Carboplatin Cisplatin Pemetrexed 5-fluorouracil Irinotecan Temozolomide | 12 Years - 85 Years | Inhibrx Biosciences, Inc | |
| Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | NCT03478462 | Pediatric Solid... Pediatric Lymph... Pediatric Brain... DIPG Neuroblastoma Ewing Sarcoma Rhabdomyosarcom... Osteosarcoma | CLR 131 | 2 Years - 25 Years | Cellectar Biosciences, Inc. | |
| HGS-ETR2 to Treat Children With Solid Tumors | NCT00428272 | Ewing's Sarcoma Osteosarcoma Neuroblastoma Rhabdomyosarcom... | Lexatumumab alo... Lexatumumab in ... Interferon gamm... Gamma 1b potent... | 1 Year - 30 Years | National Institutes of Health Clinical Center (CC) | |
| Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | NCT02581384 | Ewing Sarcoma Rhabdomyosarcom... Wilms Tumor Osteosarcoma Non-Rhabdomyosa... Renal Tumor Rhabdoid Tumor Clear Cell Rena... Sarcoma Sarcoma, Ewing Soft Tissue Sar... | Stereotactic Bo... | - 21 Years | Dana-Farber Cancer Institute | |
| Eligibility Screening for a NCI Pediatric Oncology Branch Research Study | NCT00026780 | Ewing Sarcoma Osteosarcoma Neuroblastoma Acute Lymphobla... Neurofibromatos... | - 35 Years | National Institutes of Health Clinical Center (CC) | ||
| Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery | NCT05779670 | Osteosarcoma Ewing Sarcoma Chondrosarcoma Bone Tumor | 12 Years - 90 Years | Istituto Ortopedico Rizzoli | ||
| Anlotinib and Irinotecan for Ewing Sarcoma | NCT03416517 | Ewing's Tumor M... | Anlotinib Irinotecan | 5 Years - 65 Years | Peking University People's Hospital | |
| Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | NCT03373097 | Neuroblastoma Neuroblastoma R... GD2-positive So... Osteosarcoma Ewing Sarcoma Sarcoma | GD2-CART01 | 12 Months - 25 Years | Bambino Gesù Hospital and Research Institute | |
| Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma | NCT06340204 | Ewing Sarcoma | Irinotecan Hydr... | 8 Years - 40 Years | Peking University People's Hospital | |
| A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | NCT02536183 | Pediatric Cance... Solid Tumors Rhabdomyosarcom... Ewing Sarcoma Soft Tissue Sar... Osteosarcoma Neuroblastoma Wilms Tumor Hepatic Tumor Germ Cell Tumor... | Magnetic resona... Lyso-thermosens... | - 30 Years | Children's National Research Institute | |
| A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide | NCT03495921 | Ewing Sarcoma Ewing Family of... Ewing's Tumor M... Ewing's Sarcoma... Ewing's Tumor R... Rare Diseases Sarcoma Neoplasms, Conn... Neoplasms by Hi... Neoplasms, Bone... Neoplasms, Conn... Sarcoma, Ewing Neoplasms | Vigil Irinotecan Temozolomide | 2 Years - | Gradalis, Inc. | |
| Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | NCT02581384 | Ewing Sarcoma Rhabdomyosarcom... Wilms Tumor Osteosarcoma Non-Rhabdomyosa... Renal Tumor Rhabdoid Tumor Clear Cell Rena... Sarcoma Sarcoma, Ewing Soft Tissue Sar... | Stereotactic Bo... | - 21 Years | Dana-Farber Cancer Institute | |
| Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | NCT02013336 | Recurrent or Re... Ewing Sarcoma Rhabdomyosarcom... Neuroblastoma Osteosarcoma | MM-398 (Irinote... | 12 Months - 20 Years | South Plains Oncology Consortium | |
| Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma | NCT06340204 | Ewing Sarcoma | Irinotecan Hydr... | 8 Years - 40 Years | Peking University People's Hospital | |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | NCT03220035 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor | Laboratory Biom... Vemurafenib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas | NCT03600649 | Ewing Sarcoma Myxoid Liposarc... Sarcoma,Soft Ti... Desmoplastic Sm... Extraskeletal M... Angiomatoid Fib... Clear Cell Sarc... Primary Pulmona... Myoepithelial T... Sclerosing Epit... Fibromyxoid Tum... | Seclidemstat Cyclophosphamid... Topotecan | 12 Years - | Salarius Pharmaceuticals, LLC | |
| Study in Localized and Disseminated Ewing Sarcoma | NCT00987636 | Ewing's Sarcoma | Zoledronic acid Busulfan Treosulfan | 48 Months - 50 Years | University Hospital Muenster | |
| MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | NCT02076906 | Relapsed Pediat... Refractory Pedi... Rhabdomyosarcom... Ewing Sarcoma Osteosarcoma Neuroblastoma Wilms Tumor Hepatic Tumor Germ Cell Tumor Desmoid Tumor | Magnetic Resona... | - 30 Years | Children's National Research Institute | |
| SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients | NCT04067115 | Ewing Sarcoma | Trabectedin 1 M... Irinotecan tumor biopsy 3'-Deoxy-3'-18F... | 6 Years - 99 Years | Sarcoma Alliance for Research through Collaboration | |
| Irinotecan and Temozolomide for Ewing Sarcoma | NCT03359005 | Ewing Sarcoma | Vincristine Temozolomide | - | Peking University People's Hospital | |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | NCT06395103 | B-cell Acute Ly... Diffuse Large B... Burkitt Lymphom... Neuroblastoma Ewing Sarcoma | Zilovertamab ve... | 6 Months - 25 Years | Merck Sharp & Dohme LLC | |
| A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | NCT01625351 | Ewing Sarcoma Gastrointestina... Germ Cell Tumor Hepatic Tumor Lymphoma Wilms Tumor Rhabdoid Tumor Clear Cell Carc... Renal Cell Carc... Melanoma Neuroblastoma Rhabdomyosarcom... Non-rhabdomyosa... | alemtuzumab fludarabine sirolimus Busulfan melphalan stem cells CliniMACS | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma | NCT01969942 | Ewing Sarcoma | allogeneic stem... Clyclophosphami... Fludarabina Busulfan Melphalan | - 30 Years | University of Louisville | |
| Molecular Analysis Of Solid Tumors | NCT01050296 | Pediatric Solid... | - 25 Years | St. Jude Children's Research Hospital | ||
| Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas | NCT04055220 | Bone Sarcoma Osteosarcoma Ewing Sarcoma Chondrosarcoma Undifferentiate... Leiomyosarcoma Angiosarcoma | Treatment by Re... Treatment by Pl... | 12 Years - | Centre Leon Berard | |
| Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma | NCT01610570 | Ewing Sarcoma Sarcoma | Mithramycin | 1 Year - | National Institutes of Health Clinical Center (CC) | |
| Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse | NCT04758000 | Osteosarcoma Ewing Sarcoma | Metformin Hydro... | 14 Years - | Istituto Ortopedico Rizzoli | |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | NCT03880123 | Liposarcoma Malignant Perip... Alveolar Soft P... Ewing Sarcoma Sarcoma | Selinexor Ixazomib | 14 Years - | Columbia University | |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | NCT03715933 | Solid Tumors Malignant Pleur... Gastric Adenoca... Colorectal Aden... Sarcoma Pancreatic Aden... Ewing Sarcoma Chondrosarcoma GIST SDH-deficient S... | INBRX-109 Carboplatin Cisplatin Pemetrexed 5-fluorouracil Irinotecan Temozolomide | 12 Years - 85 Years | Inhibrx Biosciences, Inc | |
| ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma | NCT02044120 | Ewing Sarcoma | niraparib Temozolomide Irinotecan | 13 Years - | Sarcoma Alliance for Research through Collaboration | |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | NCT03880123 | Liposarcoma Malignant Perip... Alveolar Soft P... Ewing Sarcoma Sarcoma | Selinexor Ixazomib | 14 Years - | Columbia University | |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | NCT06395103 | B-cell Acute Ly... Diffuse Large B... Burkitt Lymphom... Neuroblastoma Ewing Sarcoma | Zilovertamab ve... | 6 Months - 25 Years | Merck Sharp & Dohme LLC | |
| A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | NCT02536183 | Pediatric Cance... Solid Tumors Rhabdomyosarcom... Ewing Sarcoma Soft Tissue Sar... Osteosarcoma Neuroblastoma Wilms Tumor Hepatic Tumor Germ Cell Tumor... | Magnetic resona... Lyso-thermosens... | - 30 Years | Children's National Research Institute | |
| Indocyanine Green (ICG) Guided Tumor Resection | NCT04084067 | Neoplastic Dise... Solid Tumor | Indocyanine Gre... | - | St. Jude Children's Research Hospital | |
| TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss | NCT04690725 | Safety Issues Efficacy, Self | TQB3525 | 12 Years - | Peking University People's Hospital | |
| Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance | NCT06202599 | Bone Sarcoma Soft Tissue Sar... Refractory Tumo... | Fruquintinib | - | Peking University People's Hospital | |
| Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | NCT00003926 | Brain and Centr... Childhood Germ ... Chordoma Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Retinoblastoma Sarcoma | amifostine trih... busulfan filgrastim melphalan thiotepa peripheral bloo... | 1 Year - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | NCT02013336 | Recurrent or Re... Ewing Sarcoma Rhabdomyosarcom... Neuroblastoma Osteosarcoma | MM-398 (Irinote... | 12 Months - 20 Years | South Plains Oncology Consortium | |
| Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | NCT00003926 | Brain and Centr... Childhood Germ ... Chordoma Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Retinoblastoma Sarcoma | amifostine trih... busulfan filgrastim melphalan thiotepa peripheral bloo... | 1 Year - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Lurbinectedin in FET-Fused Tumors | NCT05918640 | Ewing Sarcoma Desmoplastic Sm... Pediatric Cance... Undifferentiate... | Lurbinectedin | 10 Years - | Children's Hospital of Philadelphia | |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | NCT02650401 | Solid Tumors CNS Tumors | Entrectinib | 0 Years - 18 Years | Hoffmann-La Roche | |
| Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | NCT03458728 | Relapsed or Ref... Neuroblastoma Osteosarcoma Rhabdomyosarcom... Ewing Sarcoma | Copanlisib (BAY... | 6 Months - 21 Years | Bayer | |
| Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma | NCT01882231 | Osteosarcoma Paget's Disease Ewing Sarcoma | DCE-MRI, DW-MRI... | 13 Years - | Vanderbilt-Ingram Cancer Center | |
| To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) | NCT05968768 | Ewing Sarcoma | Naxitamab | 2 Years - 21 Years | Institute of Mother and Child, Warsaw, Poland | |
| A Study of IMRT in Primary Bone and Soft Tissue Sarcoma | NCT02520128 | Soft Tissue Sar... Ewing Sarcoma Bone Sarcoma Chordoma | Intensity modul... | 16 Years - | University College, London | |
| Molecular Analysis Of Solid Tumors | NCT01050296 | Pediatric Solid... | - 25 Years | St. Jude Children's Research Hospital | ||
| Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) | NCT02624388 | Lymphoma Childhood Lymph... Solid Tumor Childhood Solid... Neuroblastoma Ewing Sarcoma Hodgkin Lymphom... Non-Hodgkin Lym... Rhabdomyosarcom... Soft Tissue Sar... Medulloblastoma Germ Cell Tumor Wilms Tumor Brain Neoplasms Medulloblastoma... Neuroectodermal... | Genistein Placebo | 1 Year - 21 Years | University of Virginia | |
| Clinical Evaluation of Neoadjuvant Chemotherapy for Primary Malignant Sarcomas That Originate in Bone | NCT03742063 | Clinical Respon... Histopathologic... Prognosis | first-line chem... | - | Peking University People's Hospital | |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | NCT03220035 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor | Laboratory Biom... Vemurafenib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | NCT00931931 | Rhabdomyosarcom... Osteosarcoma Ewing Sarcoma Soft Tissue Sar... Neuroblastoma Wilms Tumor Malignant Perip... Clival Chordoma Non-CNS Solid T... | HSV1716 | 7 Years - 30 Years | Nationwide Children's Hospital | |
| Indocyanine Green (ICG) Guided Tumor Resection | NCT04084067 | Neoplastic Dise... Solid Tumor | Indocyanine Gre... | - | St. Jude Children's Research Hospital | |
| Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma | NCT04735289 | Osteosarcoma Ewing Sarcoma | EPIC-COS Food F... Metabolome, Mic... | 12 Years - | Istituto Ortopedico Rizzoli | |
| Tabectedin to Treat Children and Adolescents With Cancer | NCT01453283 | Solid Tumors | Trabectedin (ec... | 4 Years - 16 Years | National Institutes of Health Clinical Center (CC) | |
| Trabectedin and Irinotecan for Refractory Pediatric Sarcomas | NCT02509234 | Recurrent Child... Recurrent Ewing... Recurrent Rhabd... | Combined chemot... | 10 Years - 40 Years | Technical University of Munich | |
| A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) | NCT05266196 | Ewing Sarcoma Myxoid Liposarc... Desmoplastic Sm... Extraskeletal M... Angiomatoid Fib... Clear Cell Sarc... Myoepithelial T... Low Grade Fibro... Sclerosing Epit... | Seclidemstat | 12 Years - | Salarius Pharmaceuticals, LLC | |
| HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | NCT04995003 | Sarcoma HER-2 Protein O... Osteosarcoma Rhabdomyosarcom... Ewing Sarcoma Synovial Sarcom... Soft Tissue Sar... Undifferentiate... | T cells or CAR ... Pembrolizumab I... Nivolumab Injec... | 1 Year - 25 Years | Baylor College of Medicine | |
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | NCT04483778 | Pediatric Solid... Germ Cell Tumor Retinoblastoma Hepatoblastoma Wilms Tumor Rhabdoid Tumor Carcinoma Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Synovial Sarcom... Clear Cell Sarc... Malignant Perip... Desmoplastic Sm... Soft Tissue Sar... Neuroblastoma Melanoma | second generati... second generati... Pembrolizumab | 0 Years - 26 Years | Seattle Children's Hospital | |
| Observational Study on Skeletal Ewing's Sarcoma | NCT04845893 | Ewing Sarcoma o... | Treatment of Ew... | 0 Years - 49 Years | Italian Sarcoma Group | |
| Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | NCT05302921 | Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Relapsed Pediat... Refractory Pedi... Melanoma Hepatoblastoma Hepatocellular ... Neuroblastoma Wilms Tumor | Cryoablation Th... Nivolumab Ipilimumab | 1 Year - 39 Years | Children's National Research Institute | |
| A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | NCT05135975 | Neuroblastoma Sarcoma | Cabozantinib | 18 Months - 40 Years | Nationwide Children's Hospital | |
| Clinical Evaluation for Sarcoma Originated From Bone | NCT03358992 | Sensitivity Specificity Histological Re... Survival | - | Peking University People's Hospital | ||
| Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma | NCT06340204 | Ewing Sarcoma | Irinotecan Hydr... | 8 Years - 40 Years | Peking University People's Hospital | |
| Study in Localized and Disseminated Ewing Sarcoma | NCT00987636 | Ewing's Sarcoma | Zoledronic acid Busulfan Treosulfan | 48 Months - 50 Years | University Hospital Muenster | |
| Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma | NCT02945800 | Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Soft Tissue Sar... | nab-Paclitaxel Gemcitabine | 3 Years - 30 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma | NCT06243588 | Ewing Sarcoma | clinical record... | 2 Years - | Istituto Ortopedico Rizzoli | |
| Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma | NCT01610570 | Ewing Sarcoma Sarcoma | Mithramycin | 1 Year - | National Institutes of Health Clinical Center (CC) | |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | NCT05734066 | Refractory Ewin... Relapsed Ewing ... Ewing Sarcoma | Lurbinectedin | 2 Years - 30 Years | Jazz Pharmaceuticals | |
| Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors | NCT03507491 | Cancer | Gemcitabine Nab-paclitaxel | 6 Months - 30 Years | Emory University | |
| Eligibility Screening for a NCI Pediatric Oncology Branch Research Study | NCT00026780 | Ewing Sarcoma Osteosarcoma Neuroblastoma Acute Lymphobla... Neurofibromatos... | - 35 Years | National Institutes of Health Clinical Center (CC) | ||
| Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | NCT03373097 | Neuroblastoma Neuroblastoma R... GD2-positive So... Osteosarcoma Ewing Sarcoma Sarcoma | GD2-CART01 | 12 Months - 25 Years | Bambino Gesù Hospital and Research Institute | |
| Palbociclib + Ganitumab In Ewing Sarcoma | NCT04129151 | Ewing Sarcoma Ewing's Sarcoma... | Palbociclib Ganitumab | 12 Years - 50 Years | Dana-Farber Cancer Institute | |
| TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss | NCT04690725 | Safety Issues Efficacy, Self | TQB3525 | 12 Years - | Peking University People's Hospital | |
| Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma | NCT06340204 | Ewing Sarcoma | Irinotecan Hydr... | 8 Years - 40 Years | Peking University People's Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
